HCPS and People Living with RA can Work Together on Disease Management

EXPECT MORE FROM YOUR DISEASE MANAGEMENT PLAN

The data below is based on survey totals of 15 countries. See: RA NARRATIVE WEIGHTED SURVEY METHODOLOGY

Take Action: Acknowledge the expert in you by trusting your instincts and being honest when speaking with your HCP about how you're really doing.

ra_narrative_2021_changing_the_narrative_infographic.png

RA NarRAtive surveys found that asking some patients about satisfaction with their treatment regimen may not reflect true disease control. In fact, the majority of patients (78%, n=1298/1667) who were taking prescription medicines for their RA said they were satisfied with their medication regimen, yet only (36%, n=466/1298) of those individuals would self-describe their RA as "under control."²

In addition, 52% had stopped participating in certain activities (as a result of their RA) or needed some or daily help to complete activities (n=655/1298). Furthermore, survey findings showed that 2 out of 3 surveyed physicians (n=1094/1666) reported that their patients living with RA say they feel "good enough," even though clinical assessments indicated their disease is active, and 70% of physicians (n=1169/1666) said their patients with RA often settle for a treatment that makes them feel "good enough."²

Sometimes, people living with RA can settle into a new reality, making it harder for them to notice when a treatment plan may no longer be working. The more information you share with your physician about how RA is impacting your life, the better they can work with you to develop a treatment plan that meets your needs.

If your HCP asks how you are, do you find yourself saying "I'm fine" when you really aren't? Challenge yourself to go beyond "I'm fine" to get the most out of your appointments.

For more tips on having more open conversations with your HCP - download the Conversation Guide here.

The RA NarRAtive Weighted Survey Methodology

The RA NarRAtive Patient Survey

The RA NaRAtive patient survey was conducted online by Harris Poll on behalf of Pfizer between September 4 and December 24, 2014, January 9 and 13, 2015 and September 3,2015 and January 13, 2016 among 3987 adults ages 18+ who have been diagnosed with rheumatoid arthritis (RA) in Argentina (n=217), Australia (n=481), Brazil (n=324), Canada (n=237), France (n=122), Germany (n=525), Hong Kong (n=192), Italy (n=204), Japan (n=354), South Korea (n=224), Spain (n=122), Taiwan (n=90), Turkey (n=123), the UK (n=246), and the US (n =526).²

Raw data were weighted where necessary to reflect the general adult (or online adult) population in each country (sample sizes noted above). For the global, 15-country total, a post-weight was applied to adjust for the relative size of each country's adult population within the total adult population across all countries surveyed. The unweighted sample sizes above reflect the total number of patients who completed the survey in each country, while all reported percentages are calculated based on the weighted global total described here.

Results from the RA NarRAtive patient sample survey may not reflect the experiences of the broader RA population. Raw data were not weighted at the individual country level, and are therefore only representative of the individuals who completed the survey.

The RA NarRAtive Weighted Survey Methodology

The RA NarRAtive Physician Survey

The RA NarRAtive physician survey was conducted online by Harris Poll on behalf of Pfizer between August 14 and October 2, 2015 among 1666 rheumatologists ages 18+ who have seen at least five (5) RA patients in the past month whose RA is moderately to severely active or severely active in Argentina (n=130), Australia (n=60), Brazil (n=150), Canada (n=50), France (n=149), Germany (n=150), Hong Kong (n=30), Italy (n=100),Japan (n=139), South Korea (n=100), Spain (n=100), Turkey (n=SO), Taiwan (n=100), the UK (n=150), and the US (n=20 8).³

Physician results in the US were weighted by region and years in practice by gender. In all other countries, raw data were not weighted at the individual country level (sample sizes noted above), and therefore are only representative of the individuals who completed the survey. For the global, 15-country total, a post-weight was applied to adjust for the relative size of each country's adult population within the total adult population across all countries surveyed. The unweighted sample sizes above reflect the total number of HCPs who completed the survey in each country, while all reported percentages are calculated based on the weighted global total described here.

RA NarRAtive physician sample survey may not reflect the experiences of all rheumatologists.

Raw data were not weighted at the individual country level, and are therefore only representative of the individuals who completed the survey.

Where permitted, some members of the Global RA NarRAtive Advisory Panel were paid honoraria for their participation. Pfizer provided travel and accommodation, as well as a compensation, to Advisory Panel members who represent patient advocacy organizations for time spent developing the survey and attending meetings to review the survey findings.

References:

Wolfe F., Michaud K. Resistance of rheumatoid arthritis patients to changing therapy. Arthritis Rheum. 2007; 56(7):2135-2142.
Data on File. Pfizer Inc, New York, NY. RA NarRAtive Patient Survey 2016.
Data on File. Pfizer Inc, New York, NY. RA NarRAtive HCP Survey 2016.